Reuters File Photo: COVID1 This illustration, taken on October 1, 2020, shows a sticker in front of the Johnson & Johnson logo, a vial with “Covid-1 / / coronavirus vaccine / injection” and a medical syringe.
(Reuters) – The European Union’s drug regulator on Friday identified a possible link between Johnson & Johnson’s (NYSE 🙂 Covid-1 vaccine and a rare case of deep blood clots in deep veins and suggested listing the condition as a side effect.
The European Medicines Agency recommends that immunosuppressive thrombocytopenia (ITP), a blood-borne disorder that incorrectly invades platelets in the body, information on the J&J vaccine product and an unknown frequency should be included in the vaccine of AstraZeneca (Nasdaq :). .
J&J did not immediately respond to a request for comment.
Both vaccines were previously associated with a combination of blood clots and low platelet counts known as thrombosis, including thrombocytopenia syndrome (TTS).
The two products are based on innocent vector viruses that instruct human cells to make a protein that predominates in the immune system against future coronavirus infections.
The new, possibly life-threatening clotting condition known as Venus Thromboembolism (VTE) that will be included in the J&J product label is different from TTS, the EMA said.
VTE usually begins by clotting the veins of a leg, arm, or groin, which then travels to the lungs and stops the blood supply there.
Regardless of which vaccine is used, VTE is most often caused by trauma or lack of mobility in bedridden patients. Birth control pills and some chronic conditions are also seen as risk factors.
Fusion Media Or anyone involved with Fusion Media will not assume any liability for loss or damage as a result of relying on the information contained in this website, including data, quotes, charts and buy / sell signals. Please be fully aware of the risks and costs associated with trading in the financial markets, this is one of the potential risky investment forms.